Clinical Data New Taiho, Cullian data heats up lung cancer drug battle BioPharma DiveThe findings position their drug, zipalertinib, as a threat to multiple approved medicines while setting a bar for others in testing.OncologyRead full story pharminent August 13, 2026 (Last updated: August 14, 2026) BioPharma Dive The findings position their drug, zipalertinib, as a threat to multiple approved medicines while setting a bar for others in testing. Oncology Read full story Post navigation Previous: Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps RemainNext: PTC Therapeutics Acquires Sangamo’s Fabry Disease Gene Therapy Related Stories Clinical Data Intellia finds genetic suspect for liver safety signals with ATTR gene therapy pharminent August 7, 2026 Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026
